It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming.

According to IPO research firm Renaissance Capital, 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way. To date in 2019, 23 healthcare-related companies have gone public, the most of any sector. Here’s a look… Read more »